RESUMO
The efficacy of fluconazole is related to the area under the plasma concentration-time curve (AUC) over the MIC of the microorganism. Physiological changes in critically ill patients may affect the exposure of fluconazole, and therefore dosing adjustments might be needed. The aim of this study was to evaluate variability in fluconazole drug concentration in intensive care unit (ICU) patients and to develop a pharmacokinetic model to support personalized fluconazole dosing. A prospective observational pharmacokinetic study was performed in critically ill patients receiving fluconazole either as prophylaxis or as treatment. The association between fluconazole exposure and patient variables was studied. Pharmacokinetic modeling was performed with a nonparametric adaptive grid (NPAG) algorithm using R package Pmetrics. Data from 33 patients were available for pharmacokinetic analysis. Patients on dialysis and solid organ transplant patients had a significantly lower exposure to fluconazole. The population was best described with a one-compartment model, where the mean volume of distribution was 51.52 liters (standard deviation [SD], 19.81) and the mean clearance was 0.767 liters/h (SD, 0.46). Creatinine clearance was tested as a potential covariate in the model, but was not included in the final population model. A significant positive correlation was found between the fluconazole exposure (AUC) and the trough concentration (Cmin). Substantial variability in fluconazole plasma concentrations in critically ill adults was observed, where the majority of patients were underexposed. Fluconazole Cmin therapeutic drug monitoring (TDM)-guided dosing can be used to optimize therapy in critically ill patients. (This study has been registered at ClinicalTrials.gov under identifier NCT02491151.).
Assuntos
Candidíase Invasiva , Fluconazol , Adulto , Antibacterianos , Candidíase Invasiva/tratamento farmacológico , Candidíase Invasiva/prevenção & controle , Estado Terminal , Fluconazol/uso terapêutico , Humanos , Testes de Sensibilidade Microbiana , Diálise RenalRESUMO
BACKGROUND: Candidaemia is associated with high mortality. Variables associated with mortality have been published previously, but not developed into a risk predictive model for mortality. We sought to describe the current epidemiology of candidaemia in Australia, analyse predictors of 30-day all-cause mortality, and develop and validate a mortality risk predictive model. METHODS: Adults with candidaemia were studied prospectively over 12 months at eight institutions. Clinical and laboratory variables at time of blood culture-positivity were subject to multivariate analysis for association with 30-day all-cause mortality. A predictive score for mortality was examined by area under receiver operator characteristic curves and a historical data set was used for validation. RESULTS: The median age of 133 patients with candidaemia was 62 years; 76 (57%) were male and 57 (43%) were female. Co-morbidities included underlying haematologic malignancy (n = 20; 15%), and solid organ malignancy in (n = 25; 19%); 55 (41%) were in an intensive care unit (ICU). Non-albicans Candida spp. accounted for 61% of cases (81/133). All-cause 30-day mortality was 31%. A gastrointestinal or unknown source was associated with higher overall mortality than an intravascular or urologic source (p < 0.01). A risk predictive score based on age > 65 years, ICU admission, chronic organ dysfunction, preceding surgery within 30 days, haematological malignancy, source of candidaemia and antibiotic therapy for ≥10 days stratified patients into < 20% or ≥ 20% predicted mortality. The model retained accuracy when validated against a historical dataset (n = 741). CONCLUSIONS: Mortality in patients with candidaemia remains high. A simple mortality risk predictive score stratifying patients with candidaemia into < 20% and ≥ 20% 30-day mortality is presented. This model uses information available at time of candidaemia diagnosis is easy to incorporate into decision support systems. Further validation of this model is warranted.
Assuntos
Candidemia/mortalidade , Idoso , Antifúngicos/uso terapêutico , Austrália/epidemiologia , Candida/classificação , Candida/genética , Candida/isolamento & purificação , Candidemia/tratamento farmacológico , Candidemia/epidemiologia , Candidemia/microbiologia , Feminino , Neoplasias Hematológicas/complicações , Hospitalização/estatística & dados numéricos , Humanos , Unidades de Terapia Intensiva/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Valor Preditivo dos Testes , Estudos Prospectivos , Curva ROC , Fatores de RiscoRESUMO
Donor-derived tuberculosis (TB) is an increasingly recognized complication of solid organ transplantation. We report a case of isoniazid-resistant pulmonary TB in a lung transplant recipient. The patient acquired the infection from the lung donor who was previously empirically treated with isoniazid for latent TB. The case highlights the caveat that, while adequate treatment of latent TB with isoniazid is presumed, meticulous screening of donors is required.
Assuntos
Aloenxertos/microbiologia , Antibacterianos/uso terapêutico , Antituberculosos/uso terapêutico , Fibrose Cística/cirurgia , Farmacorresistência Bacteriana , Isoniazida/uso terapêutico , Tuberculose Latente/tratamento farmacológico , Transplante de Pulmão/efeitos adversos , Mycobacterium tuberculosis/fisiologia , Tuberculose Pulmonar/etiologia , Adulto , Antibacterianos/administração & dosagem , Antibioticoprofilaxia , Antituberculosos/administração & dosagem , Bacteriemia/tratamento farmacológico , Bacteriemia/microbiologia , Líquido da Lavagem Broncoalveolar , Broncoscopia , Fibrose Cística/genética , Feminino , Fluoroquinolonas/administração & dosagem , Fluoroquinolonas/uso terapêutico , Humanos , Terapia de Imunossupressão/efeitos adversos , Isoniazida/administração & dosagem , Testes de Sensibilidade Microbiana , Moxifloxacina , Mycobacterium tuberculosis/isolamento & purificação , Pseudomonas aeruginosa/isolamento & purificação , Rifampina/administração & dosagem , Rifampina/uso terapêutico , Doadores de Tecidos , Tuberculose Pulmonar/tratamento farmacológico , Tuberculose Pulmonar/microbiologiaRESUMO
Dientamoeba fragilis is a common enteropathogen of humans. Recently a cyst stage of the parasite was described in an animal model; however, no cyst stage has been described in detail from clinical samples. We describe both cyst and precystic forms from human clinical samples.
Assuntos
Dientamoeba/citologia , Dientamebíase/parasitologia , Esporos de Protozoários/citologia , Dientamoeba/fisiologia , Humanos , Microscopia , Esporos de Protozoários/fisiologiaRESUMO
OBJECTIVES: Species-specific clinical breakpoints (CBPs) for Candida spp. were established following consideration of clinical outcomes in patients with oesophageal candidiasis. We sought to further determine the validity of the current CBPs based on data from a prospective candidaemia study. PATIENTS AND METHODS: All Candida albicans candidaemia episodes in patients enrolled in the Australian Candidaemia Study and who were treated with fluconazole monotherapy were included. Fluconazole MICs were established using Sensititre(®) YeastOne(®). RESULTS: Two hundred and seventeen evaluable episodes were identified, 93.5% of which occurred in adult patients. Fluconazole was commenced within 72 h of blood culture positivity in 96.3% (209/217) of episodes. Fluconazole doses were appropriate in 89.9% (195/217) of episodes and the median duration of therapy was 14 days (IQR 8-21 days) for the whole cohort. The all-cause 30 day mortality was 19.8% (43/217), with 37.2% (16/43) of deaths attributed to candidaemia. Classification and regression tree (CART) analysis identified a fluconazole MIC target of ≥2 mg/L for infection-related mortality and ≥4 mg/L for overall 30 day mortality. Overall mortality was no different in episodes with isolates above or below the identified MIC target, although there was a trend towards significance (Pâ=â0.051). On univariate analysis, infection-related mortality was significantly increased in C. albicans episodes with an MIC ≥2 mg/L compared with those below this MIC target (20.6% versus 4.9%; Pâ=â0.001). This target remained an independent predictor of infection-related mortality (OR 8.2; 95% CI 2.3-29.7; Pâ=â0.001). CONCLUSIONS: We observed a direct relationship between infection-related mortality and rising fluconazole MIC for C. albicans candidaemia; overall, the data support the EUCAST and revised CLSI fluconazole clinical breakpoints.
Assuntos
Candidemia/tratamento farmacológico , Candidemia/mortalidade , Doenças do Esôfago/tratamento farmacológico , Doenças do Esôfago/mortalidade , Fluconazol/uso terapêutico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antifúngicos/uso terapêutico , Candida albicans/efeitos dos fármacos , Candidemia/microbiologia , Criança , Pré-Escolar , Estudos de Coortes , Farmacorresistência Fúngica , Doenças do Esôfago/microbiologia , Feminino , Humanos , Lactente , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Estudos Prospectivos , Resultado do Tratamento , Adulto JovemRESUMO
Antifungal agents may be associated with significant toxicity or drug interactions leading to sub-therapeutic antifungal drug concentrations and poorer clinical outcomes for patients with haematological malignancy. These risks may be minimised by clinical assessment, laboratory monitoring, avoidance of particular drug combinations and dose modification. Specific measures, such as the optimal timing of oral drug administration in relation to meals, use of pre-hydration and electrolyte supplementation may also be required. Therapeutic drug monitoring (TDM) of antifungal agents is warranted, especially where non-compliance, non-linear pharmacokinetics, inadequate absorption, a narrow therapeutic window, suspected drug interaction or unexpected toxicity are encountered. Recommended indications for voriconazole and posaconazole TDM in the clinical management of haematology patients are provided. With emerging knowledge regarding the impact of pharmacogenomics upon metabolism of azole agents (particularly voriconazole), potential applications of pharmacogenomic evaluation to clinical practice are proposed.
Assuntos
Antifúngicos/administração & dosagem , Antifúngicos/efeitos adversos , Neoplasias Hematológicas/imunologia , Micoses/microbiologia , Infecções Oportunistas/microbiologia , Consenso , Esquema de Medicação , Sistemas de Liberação de Medicamentos , Cálculos da Dosagem de Medicamento , Interações Medicamentosas , Monitoramento de Medicamentos , Neoplasias Hematológicas/complicações , Neoplasias Hematológicas/terapia , Humanos , Dados de Sequência Molecular , Micoses/tratamento farmacológico , Micoses/imunologia , Infecções Oportunistas/imunologia , Infecções Oportunistas/prevenção & controle , Guias de Prática Clínica como Assunto , Soluções para Reidratação , Triazóis/administração & dosagem , Triazóis/efeitos adversos , Voriconazol/administração & dosagem , Voriconazol/efeitos adversosRESUMO
BACKGROUND: Micafungin demonstrated non-inferiority to caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in a major randomised clinical trial. AIM: The aim of this study was to investigate if micafungin is a cost-saving option compared with caspofungin for treating candidaemia and IC. METHODS: A decision analytical model was constructed to capture downstream consequences of using either agent as initial therapy for candidaemia and IC. The main outcomes were treatment success and treatment failure (i.e. death, mycological persistence, emergent infection, clinical failure but microbiological success). Outcome probabilities and treatment pathways were derived from the literature. Cost inputs were from the latest Australian resources, and resource use was estimated by expert panel. The analysis was from the Australian hospital perspective. Sensitivity analyses using Monte Carlo simulation were conducted. RESULTS: Micafungin (AU$52 816) was associated with a lower total cost than caspofungin (AU$52 976), with a net cost-saving of $160 per patient. This was primarily due to the lower cost associated with alternative antifungal treatment in the micafungin arm. Hospitalisation was the main cost-driver for both arms. The model outcome was most sensitive to the proportion of treatment success in the micafungin arm. Uncertainty analysis demonstrated that micafungin had a 58% chance of being cost-saving compared with caspofungin. CONCLUSIONS: Micafungin was cost-equivalent to caspofungin in treating candidaemia and IC, with variation in drug acquisition cost the critical factor.
Assuntos
Antifúngicos/economia , Candidemia/tratamento farmacológico , Candidemia/economia , Equinocandinas/economia , Lipopeptídeos/economia , Modelos Econômicos , Antifúngicos/uso terapêutico , Candidíase Invasiva/tratamento farmacológico , Candidíase Invasiva/economia , Caspofungina , Análise Custo-Benefício/economia , Equinocandinas/uso terapêutico , Humanos , Lipopeptídeos/uso terapêutico , Micafungina , Resultado do TratamentoRESUMO
BACKGROUND: Current Australian guidelines recommend initiating directed therapy of gentamicin if administration exceeds 48 h. Directed doses of gentamicin require the monitoring of plasma concentrations of gentamicin to determine the 24-h area under the time course of plasma gentamicin concentrations (AUC) and a dosage prediction program, for example TCIWorks or Aladdin. However, doses calculated by such programs have not been compared with an established program. AIM: To compare the directed dosage of gentamicin calculated by TCIWorks, Aladdin and an Excel-based program, with an established program, Abbottbase. METHODS: Peak and trough plasma concentrations after the first and second administered doses of gentamicin were available from three patient groups (n = 20-23) with varying creatinine clearances (<40, 40-80, >80 mL/min). The directed dose needed to produce 24-h AUC values of 80 mg.h/L was calculated using each program. RESULTS: There was a strong correlation between the directed doses predicted by each of the three programs compared with Abbottbase, following the first administered dose (r(2) > 0.97, P < 0.0001). The mean ratio (90% confidence intervals) of these directed doses of the gentamicin were: TCIWorks/Abbottbase 106% (105-107%), Aladdin/Abbottbase 102% (101-103%) and Excel/Abbottbase 108% (106-109%). The correlations and dose ratios were also similar when comparisons were made following the second administered dose. For each of the three renal function groups, all programs yielded similar directed doses. CONCLUSIONS: The four programs used in the calculation of directed doses of gentamicin yielded similar results. Any would be suitable for use in clinical practice.
Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/sangue , Gentamicinas/administração & dosagem , Gentamicinas/sangue , Guias de Prática Clínica como Assunto/normas , Software/normas , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Bases de Dados Factuais/normas , Esquema de Medicação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos TestesRESUMO
Dientamoeba fragilis is a commonly encountered trichomonad which has been implicated as a cause of gastrointestinal disease in humans. Despite the frequency of reports recording infections with this parasite, little research has been undertaken in terms of antimicrobial susceptibility. The aim of this study was to evaluate the susceptibility of D. fragilis to several commonly used antiparasitic agents: diloxanide furoate, furazolidone, iodoquinol, metronidazole, nitazoxanide, ornidazole, paromomycin, secnidazole, ronidazole, tetracycline, and tinidazole. Antibiotic susceptibility testing was performed on four clinical strains of D. fragilis, designated A, E, M, and V, respectively. Molecular testing followed, and all strains were determined to be genotype 1. The activities of antiprotozoal compounds at concentrations ranging from 2 µg/ml to 500 µg/ml were determined via cell counts of D. fragilis trophozoites grown in dixenic culture. Minimum lethal concentrations (MLCs) were as follows: ornidazole, 8 to 16 µg/ml; ronidazole, 8 to 16 µg/ml; tinidazole, 31 µg/ml; metronidazole, 31 µg/ml; secnidazole, 31 to 63 µg/ml; nitazoxanide, 63 µg/ml; tetracycline, 250 µg/ml; furazolidone, 250 to 500 µg/ml; iodoquinol, 500 µg/ml; paromomycin, 500 µg/ml; and diloxanide furoate, >500 µg/ml. This is the first study to report the profiles of susceptibility to a wide range of commonly used treatments for clinical isolates of D. fragilis. Our study indicated 5-nitroimidazole derivatives to be the most active compounds in vitro against D. fragilis.
Assuntos
Antiprotozoários/farmacologia , Dientamoeba/efeitos dos fármacos , Dientamebíase/tratamento farmacológico , Nitroimidazóis/farmacologia , Técnicas de Tipagem Bacteriana , Contagem de Células , Técnicas de Cultura de Células , Dientamoeba/genética , Dientamoeba/isolamento & purificação , Dientamebíase/parasitologia , Relação Dose-Resposta a Droga , Genótipo , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Positivas/efeitos dos fármacos , Humanos , Testes de Sensibilidade Microbiana , Trofozoítos/efeitos dos fármacosRESUMO
There are many neglected nonenteric protozoa able to cause serious morbidity and mortality in humans, particularly in the developing world. Diseases caused by certain protozoa are often more severe in the presence of HIV. While information regarding neglected tropical diseases caused by trypanosomatids and Plasmodium is abundant, these protozoa are often not a first consideration in Western countries where they are not endemic. As such, diagnostics may not be available in these regions. Due to global travel and immigration, this has become an increasing problem. Inversely, in certain parts of the world (particularly sub-Saharan Africa), the HIV problem is so severe that diseases like microsporidiosis and toxoplasmosis are common. In Western countries, due to the availability of highly active antiretroviral therapy (HAART), these diseases are infrequently encountered. While free-living amoebae are rarely encountered in a clinical setting, when infections do occur, they are often fatal. Rapid diagnosis and treatment are essential to the survival of patients infected with these organisms. This paper reviews information on the diagnosis and treatment of nonenteric protozoal diseases in immunocompromised people, with a focus on patients infected with HIV. The nonenteric microsporidia, some trypanosomatids, Toxoplasma spp., Neospora spp., some free-living amoebae, Plasmodium spp., and Babesia spp. are discussed.
Assuntos
Hospedeiro Imunocomprometido , Infecções por Protozoários/imunologia , Infecções por Protozoários/parasitologia , África Subsaariana , Amoeba/imunologia , Amoeba/patogenicidade , Terapia Antirretroviral de Alta Atividade , Feminino , Infecções por HIV/parasitologia , Infecções por HIV/fisiopatologia , Humanos , Plasmodium/imunologia , Plasmodium/patogenicidade , Gravidez , Infecções por Protozoários/diagnóstico , Infecções por Protozoários/terapia , Trypanosomatina/imunologia , Trypanosomatina/patogenicidadeRESUMO
Prototheca spp. are environmental algae that may cause serious infection in the immunocompromised patient. Clinical manifestations may mimic other diseases. We present a case of fatal infection in a 78-year-old cardiac transplant recipient and discuss pitfalls in the clinical and laboratory diagnoses.
Assuntos
Doenças Transmissíveis/etiologia , Prototheca/classificação , Prototheca/isolamento & purificação , Idoso , Doenças Transmissíveis/patologia , Meios de Cultura/química , Técnicas Citológicas , Evolução Fatal , Feminino , Transplante de Coração/efeitos adversos , Histocitoquímica , Humanos , Hospedeiro Imunocomprometido , Técnicas Microbiológicas , Microscopia , Dados de Sequência Molecular , Análise de Sequência de DNA , TransplanteRESUMO
The aim of this study was to describe the first development and evaluation of a multiplex tandem PCR (MT-PCR) assay for the detection and identification of 4 common pathogenic protozoan parasites, Cryptosporidium spp., Dientamoeba fragilis, Entamoeba histolytica, and Giardia intestinalis, from human clinical samples. A total of 472 fecal samples submitted to the Department of Microbiology at St. Vincent's Hospital were included in the study. The MT-PCR assay was compared to four real-time PCR (RT-PCR) assays and microscopy by a traditional modified iron hematoxylin stain. The MT-PCR detected 28 G. intestinalis, 26 D. fragilis, 11 E. histolytica, and 9 Cryptosporidium sp. isolates. Detection and identification of the fecal protozoa by MT-PCR demonstrated 100% correlation with the RT-PCR results, and compared to RT-PCR, MT-PCR exhibited 100% sensitivity and specificity, while traditional microscopy of stained fixed fecal smears exhibited sensitivities and specificities of 56% and 100% for Cryptosporidium spp., 38% and 99% for D. fragilis, 47% and 97% for E. histolytica, and 50% and 100% for G. intestinalis. No cross-reactivity was detected in 100 stool samples containing various other bacterial, viral, and protozoan species. The MT-PCR assay was able to provide rapid, sensitive, and specific simultaneous detection and identification of the four most important diarrhea-causing protozoan parasites that infect humans. This study also highlights the lack of sensitivity demonstrated by microscopy, and thus, molecular methods such as MT-PCR must be considered the diagnostic methods of choice for enteric protozoan parasites.
Assuntos
Cryptosporidium/isolamento & purificação , Dientamoeba/isolamento & purificação , Entamoeba histolytica/isolamento & purificação , Giardia lamblia/isolamento & purificação , Parasitologia/métodos , Reação em Cadeia da Polimerase/métodos , Infecções por Protozoários/diagnóstico , Cryptosporidium/genética , Dientamoeba/genética , Entamoeba histolytica/genética , Fezes/parasitologia , Giardia lamblia/genética , Humanos , Microscopia , Infecções por Protozoários/parasitologia , Sensibilidade e EspecificidadeAssuntos
Fármacos Anti-HIV/efeitos adversos , Darunavir/efeitos adversos , Infecções por HIV/tratamento farmacológico , Infecções por HIV/metabolismo , HIV-1 , Metabolismo dos Lipídeos/efeitos dos fármacos , Raltegravir Potássico/efeitos adversos , Ritonavir/efeitos adversos , Terapia Antirretroviral de Alta Atividade/efeitos adversos , Infecções por HIV/virologia , Hemodinâmica/efeitos dos fármacos , Humanos , Lipídeos/sangue , Resultado do TratamentoRESUMO
Dientamoeba fragilis is a pathogenic protozoan parasite that is implicated as a cause of human diarrhoea. A case-controlled study was conducted to determine the clinical signs associated with D. fragilis infection in children presenting to a Sydney Hospital. Treatment options are also discussed. Stool specimens were collected from children aged 15 years or younger and analysed for the presence of D. fragilis. In total, 41 children were included in the study along with a control group. Laboratory diagnosis was performed by microscopy of permanently stained, fixed faecal smears and by real-time PCR. Gastrointestinal symptoms were present in 40/41 (98%) of these children with dientamoebiasis, with diarrhoea (71%) and abdominal pain (29%) the most common clinical signs. Chronic gastrointestinal symptoms were present in 2% of cases. The most common anti-microbial used for treatment was metronidazole (n=41), with complete resolution of symptoms and clearance of parasite occurring in 85% of cases. A treatment failure rate occurred in 15% of those treated with metronidazole. Follow-up treatment comprised of an additional course of metronidazole or iodoquinol was needed in order to achieve complete resolution of infection and symptoms in this group. This study demonstrates the pathogenic potential of D. fragilis in children and as such it is recommended that all laboratories must routinely test for this organism and treat if detected.
Assuntos
Dientamebíase/diagnóstico , Dientamebíase/tratamento farmacológico , Metronidazol/uso terapêutico , Dor Abdominal/etiologia , Adolescente , Antiprotozoários/uso terapêutico , Austrália/epidemiologia , Estudos de Casos e Controles , Criança , Pré-Escolar , Diarreia/etiologia , Dientamoeba/fisiologia , Dientamebíase/complicações , Dientamebíase/epidemiologia , Dientamebíase/patologia , Fezes/parasitologia , Feminino , Humanos , Lactente , Iodoquinol/uso terapêutico , Masculino , Resultado do TratamentoRESUMO
Globally, the number of immunosuppressed people increases each year, with the human immunodeficiency virus (HIV) pandemic continuing to spread unabated in many parts of the world. Immunosuppression may also occur in malnourished persons, patients undergoing chemotherapy for malignancy, and those receiving immunosuppressive therapy. Components of the immune system can be functionally or genetically abnormal as a result of acquired (e.g., caused by HIV infection, lymphoma, or high-dose steroids or other immunosuppressive medications) or congenital illnesses, with more than 120 congenital immunodeficiencies described to date that either affect humoral immunity or compromise T-cell function. All individuals affected by immunosuppression are at risk of infection by opportunistic parasites (such as the microsporidia) as well as those more commonly associated with gastrointestinal disease (such as Giardia). The outcome of infection by enteric protozoan parasites is dependent on absolute CD4(+) cell counts, with lower counts being associated with more severe disease, more atypical disease, and a greater risk of disseminated disease. This review summarizes our current state of knowledge on the significance of enteric parasitic protozoa as a cause of disease in immunosuppressed persons and also provides guidance on recent advances in diagnosis and therapy for the control of these important parasites.
Assuntos
Hospedeiro Imunocomprometido , Enteropatias Parasitárias/parasitologia , Infecções Oportunistas/parasitologia , Infecções por Protozoários/parasitologia , Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Infecções Oportunistas Relacionadas com a AIDS/imunologia , Infecções Oportunistas Relacionadas com a AIDS/parasitologia , Infecções Oportunistas Relacionadas com a AIDS/patologia , Antiprotozoários/uso terapêutico , Humanos , Enteropatias Parasitárias/tratamento farmacológico , Enteropatias Parasitárias/imunologia , Enteropatias Parasitárias/patologia , Infecções Oportunistas/tratamento farmacológico , Infecções Oportunistas/imunologia , Infecções Oportunistas/patologia , Infecções por Protozoários/diagnóstico , Infecções por Protozoários/tratamento farmacológico , Infecções por Protozoários/imunologiaRESUMO
Dientamoeba fragilis is a pathogenic protozoan parasite that is notoriously difficult to diagnose. The aim of this study was to determine the gold standard for laboratory detection of D. fragilis. A total of 650 human faecal samples were included in the study. All specimens underwent the following: microscopy using a permanent stain (modified iron-haematoxylin), culture using a modified Boeck and Drbohlav's medium (MBD) and TYGM-9, a conventional polymerase chain reaction (PCR) and a real-time PCR (RT-PCR). The overall prevalence of D. fragilis in the study population was 5.4% (35/650). RT-PCR detected 35 isolates, conventional PCR detected 15 isolates, MBD culture detected 14 isolates, TYGM-9 detected ten isolates, while microscopy detected 12 isolates. RT-PCR detected an additional 15 positive samples compared to the other diagnostic methods, all of which were confirmed by sequencing. When all methods were compared to each other, RT-PCR showed a sensitivity and specificity of 100 and 100%, conventional PCR 42.9 and 100%, MBD culture 40 and 100%, TYGM-9 culture 28.6 and 100%, and microscopy 34.3 and 99%, respectively. These results show that RT-PCR is the diagnostic method of choice for the detection of D. fragilis in clinical samples and, as such, should be considered as the gold standard for diagnosis.
Assuntos
Técnicas de Laboratório Clínico/métodos , Dientamoeba/isolamento & purificação , Dientamebíase/diagnóstico , Fezes/parasitologia , Microscopia/métodos , Reação em Cadeia da Polimerase/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Técnicas de Cultura de Células/métodos , Criança , Pré-Escolar , DNA de Protozoário/química , DNA de Protozoário/genética , Dientamoeba/citologia , Dientamoeba/genética , Dientamoeba/crescimento & desenvolvimento , Dientamebíase/parasitologia , Feminino , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Sensibilidade e Especificidade , Análise de Sequência de DNA , Adulto JovemRESUMO
Dientamoeba fragilis is a pathogen of the human gastrointestinal tract that is a common cause of diarrhoea. A paucity of knowledge on the in vitro cultivation and cryopreservation of Dientamoeba has meant that few studies have been conducted to investigate its biology. The objective of this study was to define, for the first time, in vitro culture conditions able to support the long-term in vitro growth of Dientamoeba. Also, we aimed to define a suitable method for cryopreserving viable Dientamoeba trophozoites. A modified BD medium, TYGM-9, Loeffler's slope medium, Robinson's medium, Medium 199, Trichosel and a Tritrichomonas fetus medium were compared, using cell counts, for their ability to support the growth of D. fragilis at various temperatures and atmospheric conditions. Loeffler's slope medium supported significantly better growth compared to other media. A temperature of 42°C and a microaerophilic atmosphere were also optimum for Dientamoeba growth. To our knowledge, this is the first study to describe and compare different culture media and conditions for the growth of clinical isolates of D. fragilis. This new technology will aid the development of diagnostics for dientamoebiasis as well as facilitate large-scale sequencing projects that will fast track molecular studies on D. fragilis.
Assuntos
Criopreservação/métodos , Meios de Cultura , Dientamoeba/crescimento & desenvolvimento , Dientamebíase/parasitologia , Parasitologia/métodos , Animais , DNA de Protozoário/análise , DNA de Protozoário/isolamento & purificação , Dientamoeba/genética , Dientamoeba/isolamento & purificação , Dientamoeba/metabolismo , Humanos , Reação em Cadeia da Polimerase , Análise de Sequência de DNA , TemperaturaRESUMO
P2/N95 filtering face piece respirators (FFRs) protect healthcare workers (HCWs) from airborne infections. This study assessed the impact of facial hair on quantitative respirator fit in 105 male HCWs, of whom 38 were clean shaven, and assessed the prevalence of male facial hair at the study facility. Only 34 (32%) male HCWs overall achieved an adequate FFR fit, including 47% of clean-shaven men. No full-bearded HCWs achieved a fit. Adequate respirator fit decreased significantly with increasing facial hair (P<0.01 for trend). Facial hair was present on 49% of male employees. This study supports quantitative fit testing prior to P2/N95 respirator use.
Assuntos
Face , Cabelo , Dispositivos de Proteção Respiratória/normas , Adulto , Benchmarking , Desenho de Equipamento , Feminino , Pessoal de Saúde , Humanos , Masculino , Respiradores N95/normas , New South Wales , Exposição Ocupacional/prevenção & controleRESUMO
BACKGROUND: Therapeutic drug monitoring (TDM) is a tool to personalize and optimize dosing by measuring the drug concentration and subsequently adjusting the dose to reach a target concentration or exposure. The evidence to support TDM is however often ranked as expert opinion. Limitations in study design and sample size have hampered definitive conclusions of the potential added value of TDM. OBJECTIVES: We aim to give expert opinion and discuss the main points and limitations of available data from antibiotic TDM trials and emphasize key elements for consideration in design of future clinical studies to quantify the benefits of TDM. SOURCES: The sources were peer-reviewed publications, guidelines and expert opinions from the field of TDM. CONTENT: This review focuses on key aspects of antimicrobial TDM study design: describing the rationale for a TDM study, assessing the exposure of a drug, assessing susceptibility of pathogens and selecting appropriate clinical endpoints. Moreover we provide guidance on appropriate study design. IMPLICATIONS: This is an overview of different aspects relevant for the conduct of a TDM study. We believe that this paper will help researchers and clinicians to design and conduct high-quality TDM studies.